High-dose chemotherapy with or without radiotherapy followed by autologous transplantation of hematopoietic progenitor cells is an effective treatment for patients with highrisk or relapsed non-Hodgkin's lymphoma. Chemotherapy and/or hematopoietic growth factors have been used t o mobilize progenitor cells in the peripheral blood for transplantation. However, the mobilized blood cell products have been found t o be frequently contaminated with tumor cells, and techniques have not been developed t o purge tumor cells from these products. In addition, the minimum number of hematopoietic progenitor cells required for engraftment has not yet been fully elucidated. We treated 21 patients with a single infusion of cyclophosphamide (4 g/m2) followed by daily administration of granulocyte colony-stimulating factor (G-CSF). After recovery of the white blood cell count, a single 3-hour apheresis collection was performed. The apheresis product was then applied t o a discontinuous Percoll gradient. The low-density fractions resulting from this separation procedure were enriched for CD34+ progenitor cells (total cell yield, 19.5%; CD34' cell recovery, 81.2%). These e riched cellular products were treated with a panel of anti-$cell or anti-T cell monoclonal antibodies and complement in an effort t o remove residual tumor cells. After treatment of the patient with myeloablative therapies, the enriched IGH-DOSE antitumor therapy followed by autologous bone marrow (BM) transplantation is an effective treatment modality for patients with high-risk or relapsed non-Hodgkin's lymphoma (NHL).'.' Tumor cell contamination of the bone marrow has been assessed using sensitive clonogenic or molecular assays such as the polymerase chain reaction (PCR). The BM has frequently been found to be positive using PCR despite a negative determination by morphologic analysis.' Evidence that reinfusion of tumor cells in the BM can contribute to eventual relapse is emerging in 9 H
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and purged cells were reinfused. Hematologic recovery was rapid, with median neutrophil engraftment in 10 days [absolute neutrophil count (ANC), greater than 0.5 x 109/Ll and 11 days (ANC, greater than 1.0 x 109/L). Median platelet transfusion independence required 13 days. The rapidity of multilineage engraftment correlated with the number of CD34+ cells per kilogram that were infused. Patients who received more than 2 x I O 6 CD34' cells per kilogram had rapid hematologic engraftment, whereas those patients transplanted with less than 2 x I O 6 CD34+ cells per kilogram had slower platelet recovery. Modeling studies using a lymphoma cell line with a t(14;18) chromosomal translocation demonstrated the successful removal of tumor cells assayed using the polymerase chain reaction (PCR) after the processing and purging. Four of the 21 patients had PCRdetectable lymphoma cells in the bone marrow and peripheral blood; however, the enriched and purged blood products reinfused in all four did not contain detectable tumor cells. Using this approach, we developed an optimized hematopoietic progenitor cell product that retained the rapid engraftment observed with mobilized peripheral blood and contained no detectable tumor cells. a variety of clinical situations by both retrospective analysis and direct gene marking s t~d i e s .~.~ Because of the documented presence of lymphoma cells in the BM from some patients, a variety of methods have been used in an effort to purge contaminating tumor Hematopoietic progenitor cells can be found circulating in the peripheral blood.' After treatment with high-dose chemotherapy and/or hematopoietic growth factors in the form of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF ), the number of progenitor cells in the peripheral blood increases dramatically for a short period of time.'"." The presence of the hematopoietic progenitor cells in the peripheral blood can be measured by either clonogenic assays or by assessing the percentage of cells expressing the CD34 antigen. After reinfusion of the mobilized peripheral blood progenitor cells (PBPCs), more rapid engraftment of both granulocytes and platelets has been observed as compared with after transplantation of This has resulted in a decreased need for resources such as blood transfusion products and antibiotics, as well as fewer hospital days. The numbers of progenitor cells and apheresis products that are required for engraftment has not yet been clearly determined; however. even a single apheresis product has been used SUCcessfuIly."."
PBPCs have also been found to be frequently contaminated with tumor cells.1h"8 Due to the volume of multiple apheresis products and the large numbers of cells collected for the transplant procedure, a feasible purging strategy for PBPCs has not been developed. In the current study, an efficient mobilization procedure for hematopoietic progeni- tors using cyclophosphamide and G-CSF was coupled with a density gradient procedure for enriching CD34' progenitor cells, such that the PBPCs could be efficiently purged with a panel of monoclonal antibodies (MoAbs) and complement. We demonstrate that rapid engraftment can be achieved with a single apheresis product that can be successfully depleted of t( 14; 18)-positive tumor cells.
MATERIALS AND METHODS
Patients.
Patients aged 17 to 60 years with high-risk or recurrent non-Hodgkin's lymphoma were eligible for this study. Classification of lymphoma was performed according to the Working Formulation." An attempt was made to cytoreduce patients to a minimal disease state (defined as lymph nodes less than 2 cm in greatest dimension and BM involvement at less than 10%) before administration of high-dose cyclophosphamide. All patients were transplanted between August 30, 1993, and April 30, 1994. The characteristics of the 21 patients transplanted with purged PBPCs are summarized in Table 1 . All patients had histologically confirmed NHL. All patients signed an informed consent form under protocols approved by the Stanford University Hospital Institutional Review Board for the Protection of Human Subjects (Stanford, CA).
PBPC mobilization and apheresis.
Patients were hydrated and treated with cyclophosphamide (4 g/mz) administered by intravenous (IV) infusion over 2 hours through a central venous catheter. At 24 hours after the completion of the cyclophosphamide infusion, patients were treated with G-CSF (Neupogen; Amgen, Thousand Oaks, CA) administered by subcutaneous (SC) injection at a dose of approximately 10 pg/kg/d. Apheresis was initiated after recovery of the white blood cell (WBC) count to 2 1 X IO9&. Apheresis was performed using a Cobe Spectra Cell Separator (Lakewood, CO) at a rate of 80 mL/min for 200 minutes (total volume of 16 L). This cell separator enriches for mononuclear cells by centrifugation of the apheresed blood. Processing and purging was initiated when the CD34+ cell content of the apheresis collection was more than 100 CD34+ cells per microliter, and more than 12 X lo9 nucleated cells were collected during the apheresis procedure. This typically occurred on the second or third day of apheresis. Products obtained on other collection days were used as back-up material in the event of poor engraftment. Apheresis was continued until a target mean neutrophil count (MNC) of 0.5 X 108/kg was obtained.
Percoll gradient centrifugation. Percoll gradients were prepared using 2.5% steps ranging from 40% to 50% of stock solutions of Percoll (Pharmacia LKB Biotechnology, Uppsala, Sweden). Stock solutions were adjusted for pH (7.35 to 7.45) and osmolality (275 to 285 mOsm/L) using phosphate-buffered saline. Refractive indices ranged from 1.3410 (40% solution) to 1.3435 (50% solution) using a refractometer (Zeiss Oberkochen, Germany). Discontinuous gradients were layered using 6.5 mL of each of the five solutions in 50-mL tubes." On the day of processing, apheresis products were centrifuged, and the plasma was expressed. Nucleated cells were resuspended in complete media [0.9% normal saline supplemented with penicillin, gentamycin, sodium bicarbonate (1.5 milliequivalent/ L), and human serum albumin (l%)], and 2 X lo9 cells were carefully layered on each discontinuous Percoll gradient. The 50-mL tubes were centrifuged at 1,700 rpm for 30 minutes at room temperature. Cells from the interfaces between 40.0% to 42.5%, 42.5% to 45.0%, and 45.0% to 47.5% Percoll solutions (fractions 1 through 3, respectively) were collected, pooled, and washed once with complete media. These low-density cells were identified as F(l-3).
MoAb and complement purging. The following MoAbs were used in this study: anti-B cell pool: J9 (CD9). J149 (CDIO), and 4-35 (CD19) from J. Pesando (Oncomembrane Inc, Seattle, WA) and IF5 (CD20) from J. Ledbetter (Pfizer, Seattle, WA); anti-T cell pool: 35.1 (CD2), 38.1 (CD3), 64.1 (CD3), 66.2 (CD4), 10.2 (CD5), 12.1 (CD6), and 5 1.1 (CD8) from P. Martin (University of Washington, Seattle). Rabbit complement was purchased from Pel-Freez (Brown Deer, WI). Purging was performed as previously described." Briefly, the appropriate titer of MoAbs was added to the washed, pooled, Percoll gradient-enriched cells in the presence of DNAse (Worthington Biochemical, Freehold, NJ) at 100 UlmL for 30 minutes at 4°C. Rabbit complement was then added at a final concentration of either 1:s or 1:16, depending on the lot, and incubated at 37°C for 45 minutes. The cells were collected by centrifugation and resuspended in complete media, and the process was repeated. The cells were washed and resuspended in 70% autologous irradiated plasma, 10% dimethylsulfoxide (DMSO; Research Industries, Salt Lake City, UT), and 20% TC199 media (GIBCO, Grand Island, NY) and frozen in a controlled rate freezing chamber.
Fluorescence-activated cell sorting. Samples of apheresis products were stained with MoAbs conjugated with phycoerythrin (PE) against CD34 (HPCA-2; Becton Dickinson, San Jose, CA) or an isotype-matched control antibody. Other MoAbs used in this study included fluorescein-conjugated CD45RA, CD3 (Becton Dickinson), and PE-conjugated CD4 and CD8 (Becton Dickinson). Cell staining was performed as described." Stained cells were washed and analyzed using a fluorescence-activated cell sorter (FACS III; Becton Dickinson) linked to a micro VAX computer (Digital Electronic Corporation, Santa Clara, CA) equipped with FACS-Desk software (Becton Dickinson).
BM harvesting. BM collection was performed in the first 16 patients for back-up as described previously.'8 Samples for hematopoietic colony growth and PCR analysis were saved before and after purging.
Hematopoietic progenitor cell assays. Bone marrow and apherFor personal use only. on September 24, 2017. by guest www.bloodjournal.org From CSF at approximately 5 pg/kg/d IV starting on day + 1. Packed red blood cells (pRBCs) were infused when the hematocrit was less than 30%, and irradiated single-donor apheresis platelet products were administered when the platelet count was below 10 X 109L or when bleeding occurred. Assessment of engraftment included the time to reach an absolute neutrophil count (ANC) of more than 0.5 X lo9/ L and 1 X 109L and unsupported platelet counts exceeding 20 X lo9& and 50 X lo9&. Patients were hospitalized until the ANC was more than 0.5 X lo9&, they were afebrile, and they were able to support at least 50% of their nutritional needs. Statistical analysis. Statistical analysis was performed using the rank sum test. The Spearman nonparametric rank correlation coefficient (R.) was used to calculate correlations between the number of CD34+ cells infused with the time to neutrophil and platelet engraftment. The least squared method was used to calculate the fitted curve.
RESULTS
Enrichment andpurging of the PBPCs. All patients were treated with cyclophosphamide (4 dm') followed 1 day later by G-CSF (10 pglkdd). Apheresis was initiated when the WBC count exceeded 1 X 109/L and was performed on a daily basis. Previous studies had indicated that peak levels of CD34+ cells were found on the second and third day of apheresis." A median of 23.4 X lo9 (range, 12.4 X lo9 to 47.3 X lo9) nucleated cells was collected from the cell separator on the day of processing (Table 2) . These collections, which contained a median of 1.8% (0.3% to 7.8%) CD34' cells, were applied to discontinuous Percoll gradients, and the low density fractions F(l-3) were collected for further processing. These cells from F(l-3) were treated with either the anti-B cell or anti-T cell pool of MoAbs based on the immunophenotype of their tumor cells and complement. Two patients received both the anti-B cell and anti-T cell pool of MoAbs because their immunophenotype was not known. After density gradient centrifugation and purging, a median of 5.4 X lo9 (range, 1.7 X lo9 to 16.5 X 10') nucleated cells were recovered, with a cell yield of 19.5% (range, 9.1% to 55.3%). The median CD34' cell content was 7.6% (range, 0.8% to 17.9%), with a recovery of CD34+ cells of 81.2% (range, 9.9% to 302.6%; Table 2 ). The wide range in CD34' cell recovery was largely due to the difficulty in accurately determining the CD34+ cell content in the unprocessed apheresis collections, especially when present at less than 1 % of the nucleated cells. A representative FACS analysis is shown in Fig 1, where after Percoll gradient centrifugation, there was an increase in CD34' cells from 2.5% to 10.4% (Fig 1, A and B) . There was no reduction in CD34' cells after MoAb-complement (MoAb-C) purging using the anti-T cell pool of antibodies (Fig 1 C.l) . In the unfractionated apheresis product, 10.3% of the cells were positive for T-cell markers (CD3+CD4+ and CD3'CD8+). After density gradient centrifugation, the T-cell content decreased slightly (4.8%); however, cells with these T-cell markers were effectively removed after purging with the anti-T cell pool of MoAbs and complement (Fig 1 C.2) . In absolute terms, this represented a more than 10-fold depletion of T cells after the Percoll gradient centrifugation and a more than 3,500-fold depletion after MoAb-C treatment.
A median of 4.4 X lo6 (range, 0.2 X lo6 to 16.4 X lo6) CD34' cells per kilogram were obtained after processing (Table 2) . Two patients [Stanford patient numbers (SPNs) 759 and 7871 mobilized poorly, which was defined as less than 1 X lo6 CD34+ cells per kilogram in the apheresis product, and both received purged bone marrow in addition to the purged apheresis product during the transplant procedure. The apheresis products were also evaluated for hematopoietic progenitor cell colony assays. A median of 11.7 X lo4 CFU-GM per kilogram (range, 2.0 X lo4 to 53.3 X lo4) and 58.8 X IO4 BFU-E per kilogram (range, 4.3 X lo4 to 240.2 X lo4) were infused ( Table 2) .
Eficacy of PBPC purging. Two approaches were used for monitoring the removal of contaminating malignant cells. For those patients with T-cell lymphoma, FACS analysis was performed before and after purging with the panel of anti-T cell MoAbs. In all three cases of patients with T-cell lymphoma, the CD4+ and CD8' T cells were successfully depleted to below the limits of detection by FACS (Fig 1) .
In most patients, there were very few (less than 0.5%) CD19+ B cells in the apheresis collections. To detect minimal residual disease, PCR analysis was performed before and after purging with the anti-B cell panel of MoAbs. Modeling studies were performed with apheresis samples purposefully contaminated with the B-cell lymphoma cell line SU-DHU. The amplified t(14; 18) DNA sequences from the SU-DHU cells could be readily detected in the unprocessed apheresis sample and after Percoll gradient centrifugation, but not after MoAb-C purging (data not shown).
PCR analysis of the back-up BM cells before purging was positive in three patients (SPNs 722, 724, and 735). After BM purging, two patients became PCR-negative, whereas one remained PCR-positive (Table 3) . Three patients (SPNs 724,735, and 835) were found to be PCR-positive using the apheresis product. After Percoll gradient centrifugation, two patients became PCR-negative (SPNs 724 and 8 3 3 , whereas the third patient (SPN 735) remained PCR-positive. After purging, the cells of the latter patient became PCR-negative. Thus, processed PBPCs from all three patients were PCRnegative. One patient (SPN 787) had a history of PCR-positive disease at diagnosis; however, both BM and PBPC samples were PCR-negative at the time of collection (Table 3) . There was no significant reduction in the number of CD34' cells or hematopoietic progenitor cells (CFU-GM and BFU-E) after purging (data not shown).
Hematopoietic engraftment. Patients were prepared for autografting using either FTBI, etoposide, and cyclophosphamide ( 1 1 patients) or, if they were over the age of S5 years or had received prior radiotherapy, carmustine in place of the radiation (10 patients). Recovery of neutrophils (to greater than 0.5 X 1 0 9 L and greater than 1 X 1 09/L) occurred within a median of I O and 1 1 days, respectively. All patients had a neutrophil count of more than 1 X l0"L within 17 days. Platelet engraftment was also rapid, with unsupported recovery of platelets to greater than 20 X IOy& and greater than SO X 1 0 " L in a median of 13 and 17 days, respectively (Table 4) . Of the 21 patients, 17 had platelet engraftment (defined as a platelet count of more than 20 X 10"/L within 30 days); however, four patients had more prolonged thromFor personal use only. on September 24, 2017. by guest www.bloodjournal.org From A clear correlation between the rate of engraftment and the number of CD34' cells per kilogram infused was demonstrated. Although neutrophil recovery to greater than 0.5 X 109L occurred over a narrow range of 9 to 14 days, the rapidity of engraftment was statistically significantly correlated with the number of CD34+ cells per kilogram infused ( Table 4 , Fig 2A) . The time to platelet recovery was even more strikingly dependent on the number of CD34+ cells per kilogram infused. Of the 16 patients who received greater than 2 X lo6 CD34+ cells per kilogram, 15 achieved platelet counts of greater than 20 X 109/L within 30 days. Of these 16 patients, 13 achieved that level within 14 days ( Table 4 , Fig 2B) . In contrast, three of the five patients who received less than 2 X lo6 CD34+ cells per kilogram required more than 30 days to achieve an untransfused platelet count of greater than 20 X 109/L.
Although follow-up time has been short, there has been no evidence of early or late graft failure. One patient (SPN 759) died on day +61 of diffuse alveolar hemorrhage, and 21  10  12  41  15  13  32  12  10  13   17  3  36  14  17  2  12  17  15  6  15  5  19  14  NA  96  65  13  15  3  33  9  10  2  37  5  48  2  16  1  49  15  23  3  17  2  39  8  14  2  12  1  17  4   6  15  15  26  8  15  4  9  8  15  10  15  15  21  66  37  18  11  5  14  10  15  5  13  7  16  6  13  2  12  8  18  8  14  3  14  18  19  4  12  4  14  8 As very few of these patients had available tumor involved lymph node material, it is impossible to determine whether they had PCR-amplifiable chromosomal translocations at the time of diagnosis. Although it has not yet been demonstrated in a randomized clinical trial that tumor cells contaminating the infused graft are responsible for relapse of patients after autologous transplantation, several studies have found by retrospective analysis of successfully purged grafts and direct gene marking studies that contaminating tumor cells are likely to contribute to relapse.'*6 In our experience, virtually all of the patients who have occult disease within the bone marrow detected by PCR were found to have circulating tumor cells in the PBPC collections.I8 The large number of cells that are obtained by apheresis make it difficult to attempt to purge these collections. Several approaches have been used to concentrate the CD34+ cells, including the use of affinity columns and panning technique^.^^.^^ In this study, we have used the relatively simple approach of Percoll density gradient centrifugation to enrich for CD34+ cells. Using this technique, the CD34' cells were enriched in the low-density fractions such that the number of peripheral blood mononuclear cells required for purging was reduced by approximately 80%.
There are several possible interventions that could contribute to tumor cell reduction in the PBPC collections. The first is the use of chemotherapy in the form of cyclophosphamide for progenitor cell mobilization. Previous studies in solid tumors have indicated that tumor cell depletion occurs in some patients, whereas others have reported a mobilization of tumor cells and hematopoietic progenitor cells.31 Reduction of the tumor cell load may occur during the Percoll gradient enrichment for the CD34+ cells. In fact, PBPCs
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From from two patients were found to be PCR-positive before the Percoll gradient, but the low-density cell fraction was PCRnegative. Finally, the MoAb-C purging typically results in tumor cell depletion of approximately 3 logs." In one patient, the PBPCs were found to be PCR-positive after the Percoll gradient centrifugation and became PCR-negative after the purging procedure. In sum, all of the CD34+ cellenriched and MoAb-C-purged PBPC collections were PCRnegative. However, the small number of t(14; 18)-positive patients makes it difficult to determine whether this approach will routinely result in enriched products that are uniformly PCR-negative.
Hematologic engraftment after myeloablative therapy and infusion of the purged PBPCs was rapid. Myeloid engraftment was achieved in a median of 10 days, platelet engraftment in a median of 13 days, and hospital discharge in a median of 15 days after the transplant. This compares favorably to our previous experience of patients treated with an identical regimen who received purged BM, where myeloid engraftment was achieved in a median of 16 days, platelet engraftment in a median of 36 days, and hospital discharge in a median of 28 days after transplantation." The absolute number of CD34+ cells per kilogram required to achieve a successful graft is not known with certainty. Previous studies have suggested that patients who received more than 5 X lo6 CD34' cells per kilogram have rapid multilineage engraftment.26 In another study, there was only a weak correlation between the number of CD34+ cells per kilogram infused and the rate of engraftment; however, most of these patients received high numbers of CD34+ cells.I4 In our study, all of the patients who received more than 2 X lo6 CD34' cells per kilogram (16 of 21 patients) had rapid recovery of both neutrophils and platelets. Two patients mobilized poorly and received their purged BM in addition to the purged PBPCs. These two patients engrafted rapidly with respect to neutrophils. However, one of these patients had prolonged thrombocytopenia. Three additional patients had between 1 X lo6 and 1.5 X lo6 CD34+ cells per kilogram and in two of these patients, platelet recovery required more than 40 days despite rapid myeloid engraftment. One of these patients was given stored purged BM on day +39 because of poor platelet recovery. The factors that predict which patients mobilize CD34+ cells poorly are not known; however, several of these patients were heavily pretreated with multiple combinations of chemotherapy. These results suggest that a PBPC product that contains more than 2 X lo6 CD34+ cells per kilogram is likely to result in rapid multilineage engraftment.
Patients who underwent autografting with this approach were able to tolerate the aggressive therapeutic preparative regimen exceptionally well. The decreased use of resources in the form of transfusional support, antibiotics, and length of hospital stay is an important consideration. Excellent results with autologous transplantation in patients with NHL have been reported using the preparative regimens used in this s t~d y .~~.~~ However, relapse remains the major reason for failure in these patients. Indeed, several patients who have received purged PBPCs have relapsed despite being transplanted with PCR-negative material. New therapeutic approaches to posttransplant immunomodulation may be required to improve these results.
Several small series of high-risk NHL patients transplanted in first complete remission have reported an improved outcome compared with historical ~o n t r o l s .~' .~~ The use of purged PBPCs may allow for the more routine application of autologous transplantation for NHL patients.
